CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: However, molecular mechanisms of PAK6-mediated drug resistance are largely unknown; in particular, PF-3758309 could reduce mitochondrial staining and ROS production in TKI-nonresponder CD34+ CML cells, indicating metabolic effects that require further investigation [12].